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ABSTRACT 
There is a growing body of research to suggest that Human Immunodeficiency Virus (HIV) 
infection is associated with an increased risk for myocardial infarction (MI) although the 
underlying processes remain unclear. An assessment of MI risk using a commonly-available 
measure of the immune status is therefore of Public Health importance. CD8+ and CD4+ T-cell 
counts are periodically measured in the routine management of HIV-infected patients. However, 
CD8+ T-cell counts are often not reported or are simply incorporated into the calculation of a 
CD4+/CD8+ ratio. Total CD8+ T-cell counts have been shown to be associated with an increased 
risk for MI in at least one recent study. A few other studies have examined this association 
indirectly by using the CD4+/CD8+ ratio, but only considered MI surrogates (e.g. subclinical 
coronary atherosclerosis) as an outcome. Also, measuring cell-surface markers of CD8+ T-cell 
activation and HIV-specific CD8+ T cell counts is costly and often not requested in the routine 
management of HIV infection. 
This study investigated the association between total CD8+ T-cell counts and MI risk 
among a large cohort of HIV-uninfected and HIV-infected Veterans. Using Cox proportional 
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hazard  regression models, the results suggest that MI risk is associated with a high CD8+ T-cell 
count of ≥1066 cells/ mm3 (Adjusted HR = 1.82, P <0.001, 95% CI: 1.46 to 2.28). They also 
suggest that the risk for MI posed by total CD8+ T-cell counts should be interpreted in the 
context of CD4+ T-cell clinical cut-points, or the overall immune status. The degree of MI risk in 
the cohort differed depending on the level of the immunosuppression. Total CD8+ T cell-counts 
seemed to modestly improve the risk stratification provided by CD4+ T-cell clinical cut-points, 
though the mechanisms are still unclear. Future studies will be instrumental in understanding the 
role of the immune system in MI risk prediction. 
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1.0  INTRODUCTION 
1.1 BACKGROUND 
It has been observed that HIV-infected persons are at a higher risk for the development of 
myocardial infarction (MI) and other cardiovascular diseases compared to HIV-uninfected 
persons [1-5]. In the natural history of Human Immunodeficiency Virus (HIV) infection, CD4+ 
and CD8+ T-cell counts follow a characteristic pattern (Figure 1) [6-8]. Within the first two 
weeks following HIV infection, there is a large drop in the CD4+ T-cell count while the CD8+ T-
cell count rises, but these levels soon regain near-normalcy. In the ensuing period, a strong 
cytotoxic immune response then occurs to achieve viremic control – large numbers of HIV viral 
particles are produced yet destroyed each day [6, 9]. Since most of the viral particles come from 
recently infected CD4+ T cells, the CD4+ T-cell count gradually declines as these cells are 
destroyed both by the virus and the immune system in the course of the infection. Spontaneous 
apoptosis of uninfected CD4+ and CD8+ T cells also occurs [6]. CD8+ T-cell levels, however, 
remain persistently elevated.  
Immune activation, in of itself, does not appear to be solely responsible for the high 
CD8+ T-cell count. Rather, it has been demonstrated to be possibly due to homeostatic 
mechanisms to maintain the circulating T-cell pool [10]. Studies suggest that eventually, the 
persistent immune activation (of CD4+ and CD8+ T cells) from viral particles that are released 
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from latent reservoirs of continuous HIV replication, such as lymph nodes, leads to exhaustion of 
quiescent naïve T cells available to replace them [11].  
  
Figure 1. Natural History of HIV 
Reproduced with permission: 
Richard Hunt http://pathmicro.med.sc.edu/lecture/hiv_time_course2.jpg 
 
 
Thus, at this stage CD8+ T-cell levels drop dramatically, viremic control is lost and the 
individual becomes more prone to co-morbid disease, opportunistic infections and eventually 
AIDS. At late stages of HIV infection, mutant HIV virus particles are also able to directly infect 
CD8+ T cells and destroy them, further contributing to the low CD8+ T-cell count and 
immunodeficiency [6]. 
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1.2 MOTIVATION FOR THE STUDY 
Such findings have led to the question of whether a HIV-infected person’s immune status could 
be indicative of the risk of MI [2]. Indeed, changes in the levels of CD4+ and CD8+ T cells have 
already been used as predictors for the progression to Acquired Immune Deficiency Syndrome 
(AIDS) [12-15]. It is also of interest whether a clinically-relevant measure of immune status 
could be demonstrated to consistently describe MI risk. 
Previous studies have enumerated the usefulness of CD4+ T-cell counts (and traditional 
risk factors such as hypertension, smoking, and diabetes, for example) in determining the risk of 
MI (or its surrogates) in HIV [2, 16, 17]. However, a MEDLINE®/PubMed® search of available 
literature revealed that as yet only one study had investigated the association between CD8+ T-
cell counts with MI risk in HIV [2]. The paucity of research into the predictive role of total CD8+ 
T-cell counts associated with MI risk may be related to inconsistent results from studies 
attempting to associate these counts with HIV progression to AIDS: both significant [18, 19] and 
non-significant [20, 21] relationships have been reported. Some studies have demonstrated that 
immune activation may be associated with an increased risk of MI [16, 17], by focusing on 
biomarkers of immune activation and the CD4+/CD8+ ratio [2]. These latter studies had some 
limitations in that they investigated surrogates of MI (e.g. subclinical carotid artery disease) and 
had relatively small sample sizes. Hence, the exact prognostic role of the CD8+ T-cell count in 
this process has not been clearly shown.  
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1.3 PURPOSE OF THE STUDY 
This study sought to investigate if any potential association exists between the total CD8+ T-cell 
count and the risk of MI in a large cohort of HIV-infected and HIV-uninfected persons, adjusting 
for common traditional cardiovascular risk factors as well as HIV-specific parameters. Cases of 
fatal MI were also included in this study as they have sometimes been excluded in studies 
associating HIV with MI risk [22-24]. The implications of this research are of Public Health 
significance: Total CD8+ T-cell counts are often obtained during routine care of HIV-infected 
persons but are usually used in the calculation of a CD4+/CD8+ T-cell ratio [25]. This may not be 
wholly informative as the natural history of HIV (Figure 1) shows that the ratio could be very 
similar at different stages of disease. Hence, use of both total CD4+ and CD8+ T-cell counts in 
characterizing the immune status’ association with MI risk could provide a measure that is of 
immediate relevance to clinical practice settings and could lead to an improvement in care of 
HIV-infected persons. The results of this study may also offer a better understanding of the 
immune system’s role in the risk of MI in HIV-infected persons.  
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2.0  METHODS 
2.1 STUDY POPULATION 
A sample of 73,398 Veterans was derived from the U.S. Veterans Aging Cohort Study – Virtual 
Cohort (VACS-VC) [26, 27] for the study period between April 1, 2003 to December 31, 2009. 
This virtual cohort was created from VACS, an ongoing prospective, longitudinal cohort study 
group of HIV-infected Veterans matched (1:2) with HIV-uninfected Veterans based on 
demographic factors (including age and race) and Veterans Affairs Medical Center (VAMC) 
clinic site at which they were enrolled [27]. The VACS-VC has been in existence since 1998, 
utilizing a national electronic medical system from the U.S. Department of Veterans Affairs, 
such that matched Veterans are those enrolled in the same calendar year. The cohort comprises 
of data from at least five databases including the National Patient Care Database, the 
Immunology Case Registry, the Health Factor Dataset, the National Pharmacy Benefits 
Management Database, and the Decision Support System. 
For better event ascertainment in this study, these data were combined with information 
from the Veterans-specific Ischemic Heart Disease Quality Enhancement Research Initiative 
(IHD-QUERI) database [28], and Medicare and Medicaid databases. Using the Veterans Health 
Administration’s Medical SAS® inpatient datasets [29] as well as the Veterans Affairs vital 
status electronic file, any MI-related deaths within the VACS-VC were identified. Information 
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from the Social Security Administration Death Master file and the Beneficiary Identification and 
Records Locator subsystem were also utilized in this identification process. The National Death 
Index was used to obtain information on the probable cause of death. 
All participants provided written, informed consent. Institutional Review Board (IRB) 
approval for this study was obtained from the IRBs of the West Haven VAMC, Yale University 
and the University of Pittsburgh. 
The selected sample from the VACS-VC consisted of 73,398 persons who were enrolled 
in VACS on or after April 1, 2003 and were free of pre-existing cardiovascular disease, 
including MI (based on clinical diagnosis and/ or International Classification of Diseases, 9th 
revision (ICD-9) codes). The baseline date was thus a participant’s first clinic visit on or after 
April 1, 2003. Participants were then followed until the development of MI, death or the last 
observed follow-up date selected for this study (December 31, 2009). 
2.2 DEPENDENT VARIABLE 
This was incident MI, i.e. all new cases of definite or probable MI [30] in the VACS-VC for the 
follow-up period aforementioned. MI events that were completely managed in non-VA hospitals 
were identified using inpatient ICD-9 code 410 data in the Medicare database, as has been 
utilized previously [1]. MI associated with death was of two types, using criteria by Ives et al – 
mortality within thirty days of MI diagnosis was classified as definite fatal MI, while death 
certificates noting mortality to be primarily a result of MI resulted in another class termed 
probable fatal MI [30]. 
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Adjudicated MI events were used to minimize ascertainment bias. Following the 
Universal Definition of Myocardial Infarction guidelines [31], proper adjudication for MI 
included the existence of serially raised cardiac enzymes, Troponin I (or Troponin T) and 
Creatine Kinase MB fraction (CK MB), deemed significant for MI based on the laboratory assay 
used. Equally utilized was the presence of characteristic electrocardiogram (EKG) findings, 
especially ST segment elevation of ≥0.1mV in any two or more contiguous EKG leads (except 
V2 and V3 leads), with or without the presence of left bundle branch heart block – an interruption 
in the electrical conduction pathway of the heart muscle that makes the left ventricle contract 
slower than the right ventricle instead of synchronously. Adjudication of MI events that were 
managed solely in hospitals other than the VAMC without transfer to a VA facility required the 
use of Medicare inpatient ICD-9 code 410 data, as has been employed in a previous study [1]. 
Using the Compensation and Pension Records Interchange (CAPRI) information service access 
[32], MI diagnosis was sought from electronic medical records for VACS-VC participants, with 
due consideration of discharge summary documentation, laboratory test results and inpatient/ 
outpatient ward and/or clinic reviews.  
2.3 PREDICTOR VARIABLES 
2.3.1 Primary Independent Variable 
The main independent variable of interest was the total CD8+ T-cell count recorded at baseline. 
As CD8+ T-cell counts were available only for Veterans that were HIV-seropositive, study 
participants were classified as being either HIV-uninfected, or HIV-infected with CD8+ T-cell 
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tertiles of ≤666, 667–1065 and ≥1066 cells/ mm3 at baseline. In separate analyses, the total CD8+ 
T-cell count variable was stratified by baseline CD4+ T-cell level categories of clinical 
importance [33]. Baseline CD8+ T-cell count was also assessed as a continuous variable for HIV-
infected participants. 
2.3.2 Covariates 
Data on demographic variables, traditional cardiovascular risk factors [34, 35] of high blood 
pressure, high lipid levels, obesity, diabetes, and smoking were obtained from medical records 
and ICD-9 codes. Other covariates identified were renal disease, substance abuse (cocaine and 
alcohol), Hepatitis C virus infection, anemia, and use of statins. Data on HIV viral load and 
antiretroviral therapy were also included for HIV-infected participants.  
2.3.2.1 Blood pressure 
Blood pressure measurement at baseline was the average of three routine outpatient observations 
closest to the date of enrollment. Using the Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) definition for 
hypertension [36], participants were stratified as being either non-hypertensive (i.e. <140/90 
mmHg  and not on anti-hypertensive medication) or controlled-hypertensive (i.e. <140/90 mmHg  
and on anti-hypertensive medication) or uncontrolled-hypertensive (i.e. ≥140/90 mmHg).  
2.3.2.2 Lipid levels 
Lipid level measurements were of high density lipoprotein (HDL) cholesterol levels, low density 
lipoprotein (LDL) cholesterol levels and triglyceride (TG) levels and classified following the 
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National Cholesterol Education Program, Adult Treatment Panel III (NCEP, ATP III) clinical 
guidelines [37]. LDL cholesterol levels were optimal (<100 mg/dL), above optimal (100-129 
mg/dL), borderline high (130-159 mg/dL), and high to very high (160 mg/dL and above). HDL 
cholesterol levels were high (60 mg/dL and above), or low (< 40mg/dL), TG levels were optimal 
to normal (<150 mg/dL) or borderline high to high and very high – broadly grouped as being 
‘elevated’ – (150 mg/dL and above).  
2.3.2.3 Obesity 
Obesity was defined as a body mass index (BMI) of 30 kg/m2 and above [38].  
2.3.2.4 Renal Disease 
Renal disease was classified using clinical practice guidelines [39], based on estimated 
glomerular filtration rate (eGFR), as normal kidney function to mild chronic kidney disease (≥60 
mL/min/1.73m2), moderate chronic kidney disease (30-59 mL/min/1.73m2), or severe kidney 
disease to kidney failure (<30 mL/min/1.73m2) .  
 
2.3.2.5 Diabetes 
Diabetes was identified as being either present or absent in as per medical record documentation 
and ICD-9 codes using an algorithm that has been previously employed [1, 40, 41].  
2.3.2.6 Smoking History 
Participants’ smoking history was classified as either ‘never smoked’, ‘previously smoked’ or 
‘currently smoking’ [1].  
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2.3.2.7 Substance Abuse 
Cocaine and alcohol abuse were defined as being present or absent using ICD-9 codes [1, 42].  
2.3.2.8 Hepatitis C Virus Infection 
Hepatitis C virus infection was deemed present if a laboratory diagnosis or ICD-9 codes for one 
or more inpatient records or two or more outpatient records identified this infection [1, 43].  
2.3.2.9 Hemoglobin Concentration 
For persons older than 15 years, the World Health Organization [44] defines the threshold for 
anemia in males and in non-pregnant females as 13 g/dL and 12 g/dL respectively. Thus 
hemoglobin concentration was categorized in 0.1 unit decrements as ≥14.0 g/dL (normal), 12.0-
13.9 g/dL, 10-11.9 g/dL and ≤10g/dL (the concentration at which transfusion may begin to be 
indicated).  
2.3.2.10 Covariates Specific to HIV-Infected Veterans 
For HIV-infected Veterans, HIV-1 RNA viral load and CD4+ T cell count were also obtained at 
baseline. Antiretroviral therapy (ART) use was categorized as either: (1) none, (2) a combination 
of Nucleoside Reverse Transcriptase Inhibitors with a Non-Nucleoside Reverse Transcriptase 
inhibitor (NRTI + NNRTI), (3) a combination of NRTI with a Protease Inhibitor (PI), or (4) 
some other drug combination. It has been reported that most Veterans obtain ART within the VA 
system [27]. 
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2.4 STATISTICAL METHODS AND ANALYSES 
As the primary aim of the study was to investigate the prognostic value of CD8+ T-cell levels in 
the setting of HIV, the study participants were first stratified by HIV status and then HIV-
infected Veterans were further stratified by baseline CD8+ T-cell counts (in tertiles). Based on 
this categorization, differences in the independent variables were compared. Pearson’s Chi-
squared tests of independence were used to assess categorical variables. The Pearson’s Chi-
squared test assumes that the observations are a simple random sample from the population 
where each participant had an equal probability of selection, assumes that the overall sample is 
‘large’ (often greater than 30), assumes that expected ‘table cell’ counts are not less than five in 
80% of the cells, and assumes that observations are independent of each other. Continuous 
variables were assessed using either Analysis of Variance (ANOVA) tests or the Kruskal-Wallis 
One way ANOVA test if necessary. ANOVA is a parametric test, meaning it is used for data that 
follow a normal or asymptotically-normal distribution, used to compare the equality of means of 
several different groups. The Kruskal-Wallis test is a non-parametric test, meaning it is used for 
data that do not have a normal or asymptotically-normal distribution assumption. However it 
does assume that the distributions of the variables have a similar shape and scale.  
Using the following general formula:  
Incidence rate =  
incidence rates of MI per 10,000 person-years of follow-up were calculated for each of the HIV-
CD8+ T-cell categories. Rates for mortality from any cause per 10,000 person years were also 
calculated. Additionally, the CD8+ T-cell tertiles were stratified by baseline CD4+ T-cell levels 
of clinical importance and rates were calculated for these new categories as well. Ninety-five per 
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cent confidence intervals for each of the rates were estimated using a quadratic approximation to 
the Poisson log likelihood for the log rate parameter [45]. 
2.5 REGRESSION MODELS 
Cox proportional hazard regression models [46] were then used to determine the association 
between baseline CD8+ T-cell counts and MI in terms of hazard ratios, 95% confidence intervals 
and P values, adjusting for all of the covariates. A proportional hazards model is a regression 
model used in time-to-event analyses whereby the intensity with which the event occurs (its 
hazard or risk) is multiplicatively proportional to some function of the hazard which all members 
in the cohort face (the baseline hazard rate, ). 
Mathematically, 
 
and 
 =  
where  and  are the hazard rates of the jth and mth persons in a dataset, 
with  and  as their respective covariates,  as the respective beta-coefficients of these 
covariates, and with the caveat that  and  are assumed to remain constant over time [47]. 
The baseline CD8+ T-cell count was assessed in separate models as a categorical and 
continuous variable. Another proportional hazards model was also created in which the 
 12 
categorical CD8+ T-cell count was stratified by clinically-important CD4+ T-cell count 
categories.  A separate proportional hazards model for HIV-infected participants was also 
constructed to include the effects of HIV viral load, baseline CD4+ T-cell measurements and 
antiretroviral therapy as covariates. Separate models with and without baseline CD4+ T-cell 
measurements were compared to eliminate possible collinearity. Assumptions of proportional 
hazards were also checked using scaled Schoenfeld residuals tests. Kaplan-Meier survival 
estimates were calculated to describe survival time to MI for the CD8+ T-cell categories.   
Stata® software package, version 12, was used for all statistical analyses. 
2.6 MISSING DATA 
Proper statistical inference may be hindered in the presence of missing data, especially in large 
datasets [48]. Multiple imputation is a widely-accepted statistical technique for handling missing 
data and involves the replacement of a missing value by two or more imputed, plausible values, 
thereby creating simulated datasets containing each of these values [48]. The imputed datasets 
are analyzed separately by standard procedures and then their results are averaged. In this study, 
missing data was assumed to be missing at random and multiple imputation techniques were 
used to generate five datasets in order to handle the missing data for the covariates. The choice of 
five sets of imputations follows the recommendation by Rubin [48].  
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3.0  RESULTS 
3.1 BASELINE CHARACTERISTICS 
A total of 73,398 study participants were included in the study and followed for a total period of 
about 6.8 years. The majority was male with a median age of 48 years (mean ± SD = 48.5 ± 9.3, 
Table 1). Participants were categorized as being either HIV-uninfected, or HIV-infected within 
the lowest, intermediate or highest baseline CD8+ T-cell tertile (i.e. ≤666 cells/mm3, 667–1065 
cells/mm3 and ≥1066 cells/mm3 respectively). Despite prior matching at enrollment into the 
VACS, members of the sample from the virtual cohort still differed by HIV-CD8+ T-cell tertile 
status for almost all covariates (P ≤0.004 for substance abuse, P ≤0.001 for others). No 
significant differences were seen in the use of Non-Nucleoside Reverse Transcriptase Inhibitor 
medication (NNRTI) among HIV-infected participants (P = 0.423). Additionally, low HDL 
cholesterol and elevated Triglycerides were highest among HIV-infected participants in the 
highest CD8+ tertile. 
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Table 1. Baseline Characteristics of HIV-Infected and Matched HIV-Uninfected Veterans, 
Stratified by CD8+ T-cell Levela 
(continued) 
Baseline Characteristics 
HIV-uninfected 
(n = 55,109) 
HIV-infected 
(n = 18,289) 
CD8+ lowest 
tertile 
(≤666 cells/mm3) 
(n = 5,987) 
CD8+ 
intermediate 
tertile 
(667 – 1065 
cells/mm3) 
(n = 6,185) 
CD8+ highest 
tertile 
(>1066 cells/mm3) 
(n = 6,117) 
Age (years), n  
(median ± IQR, 
 mean ± SD) 
55,109  
(49.00 ± 11.00, 
48.76 ± 9.24) 
5,987 
(48.00 ± 12.00, 
48.02 ± 9.28)  
6,185 
(48.00 ± 13.00, 
47.54 ± 9.37) 
6,117 
(48.00 ± 12.00, 
47.90 ± 9.27) 
Males (n, %) 53, 572 (97.21%) 5,813 (97.09%) 6,050 (97.82%) 5,988 (97.89%) 
Race/ethnicity (n, %) 
 African American 
 Hispanic  
 White 
 Other 
26,358 (47.83%) 
4,294 (7.79%) 
20,827 (37.79%) 
3,630 (6.59%) 
2,999 (50.09%) 
524 (8.75%) 
2,077 (34.69%) 
387 (6.46%) 
2,869 (46.39%) 
459 (7.42%) 
2,441 (39.47%) 
416 (6.73%) 
2,887 (47.20%) 
423 (6.92%) 
2,434 (39.79%) 
373 (6.10%) 
Traditional CHD risk factors 
Blood pressure (BP) (n, %) 
 Non-hypertensive 
 Controlled-hypertensive 
 Uncontrolled-hypertensive 
31,522 (58.41%) 
5,210 (9.65%) 
17,236 (31.94%) 
4,098 (69.05%) 
443 (7.46%) 
1,394 (23.49%) 
4,133 (67.38%) 
432 (7.04%) 
1,569 (25.58%) 
4,035 (66.55%) 
404 (6.66%) 
1,624 (26.79%) 
Diabetes (n, %) 11,385 (20.66%) 724 (12.09%)  806 (13.03%)  954 (15.60%) 
Lipid profile (n, %) 
 Triglycerides ≥ 150 mg/dL  
 HDL cholesterol ≥ 60  mg/dL 
 HDL cholesterol 40 - 59  mg/dL 
 HDL cholesterol < 40  mg/dL 
 LDL cholesterol <100  mg/dL 
 LDL cholesterol 100-129  mg/dL 
 LDL cholesterol 130-159  mg/dL 
 LDL cholesterol ≥ 160  mg/dL 
16,247 (38.24%) 
5,980 (14.76%) 
19,161 (47.28%) 
15,382 (37.96%) 
12,223 (31.70%) 
12,842 (33.30%) 
8,783 (22.78%) 
4,715 (12.23%) 
2,186 (43.41%) 
   621 (13.90%) 
1,692 (37.84%) 
2,157 (48.27%) 
2,152 (50.80%) 
1,155 (27.27%) 
 598 (14.12%) 
 331 (7.81%) 
2,587 (47.89%) 
  504 (10.54%) 
1,832 (38.33%) 
2,444 (51.13%) 
2,071 (44.93%) 
1,376 (29.84%) 
 762 (16.52%) 
 401 (8.72%) 
2,918 (54.47%) 
 372 (7.91%) 
1,682 (35.77%) 
2,648 (56.32%) 
2,046 (44.87%) 
1,391 (30.50%) 
 739 (16.21%) 
384 (8.42%) 
Body Mass Index ≥ 30kg/m2 
(n, %) 
20,762 (38.78%)  632 (10.67%)  836 (13.63%) 1,006 (16.57%) 
Smoking history (n, %) 
 Never 
 Past 
 Current 
15,235 (29.95%) 
8,154 (16.03%) 
27,487 (54.03%) 
1,582 (28.19%) 
  744 (13.26%) 
3,286 (58.55%) 
1,615 (27.41%) 
   767 (13.02%) 
3,509 (59.57%) 
1,630 (28.12%) 
   803 (13.85%) 
3,363 (58.02%) 
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Table 1 (continued)
Baseline Characteristics 
HIV-uninfected 
(n = 55,109) 
HIV-infected 
(n = 18,289) 
CD8+ lowest 
tertile 
(≤666 cells/mm3) 
(n = 5,987) 
CD8+ 
intermediate 
tertile 
(667 – 1065 
cells/mm3) 
(n = 6,185) 
CD8+ highest 
tertile 
(>1066 cells/mm3) 
(n = 6,117) 
Other risk factors 
Hepatitis C virus infection (n, %) 8,591 (15.59%) 2,154 (35.98%) 2,062 (33.34%) 1,954 (31.94%) 
Estimated Glomerular Filtration 
Rate (eGFR) (n, %) 
 eGFR ≥ 60 mL/min/1.73m2
 eGFR  30 - 59 mL/min/1.73m2
 eGFR < 30 mL/min/1.73m2 
45,837 (95.19%) 
 2,037 (4.23%) 
    281 (0.58%) 
5,321 (92.64%) 
 318 (5.54%) 
 105 (1.83%) 
5,567 (94.12%) 
 282 (4.77%) 
   66 (1.12%) 
5,490 (93.53%) 
 313 (5.33%) 
   67 (1.14%) 
Use of Statins (n, %) 5,393 (9.79%)  311 (5.19%)  433 (7.00%)  479 (7.83%) 
Hemoglobin (Hb) (n, %) 
 Hb ≥ 14.0 g/dL 
 Hb 12.0 – 13.9 g/dL 
 Hb 10.0 – 11.9 g/dlL 
 Hb < 10.0 g/dL 
33,788 (72.46%) 
10,906 (23.39%) 
 1,554 (3.33%) 
    383 (0.82%) 
2,543 (46.41%) 
1,894 (34.56%) 
 729 (13.30%) 
 314 (5.73%) 
3,436 (60.50%) 
1,731 (30.48%) 
 406 (7.15%) 
 106 (1.87%) 
3,537 (62.09%) 
1,702 (29.88%) 
 363 (6.37%) 
   95 (1.67%) 
History of Substance Use 
Cocaine abuse or dependence 3,968 (7.20%)  705 (11.78%)  654 (10.57%)  586 (9.58%) 
Alcohol  abuse or dependence  7,265 (13.18%)  851 (14.21%)  792 (12.81%)  736 (12.03%) 
Baseline Laboratory Analysis 
CD4+ T-cell level 
≥500 cells/ mm3 
200 – 499 cells/ mm3 
<200 cells/ mm3 
…
…
… 
1,097 (20.36%) 
1,901 (35.29%) 
2,389 (44.35%) 
1,971 (35.27%) 
2,447 (43.78%) 
1,171 (20.95%) 
2,354 (41.86%) 
2,382 (42.36%) 
887 (15.77%) 
HIV-1 RNA copies/ mL 
<500 copies/ mL 
≥500 copies/ mL 
… 
… 
2,388 (43.66%) 
3,081 (56.34%) 
2,680 (47.33%) 
2,982 (52.67%) 
2,428 (42.52%) 
3,282 (57.48%) 
Antiretroviral therapy use 
(n, %) 
 None 
 NRTI + NNRTI 
 NRTI + PI 
 Other combination 
…
…
…
… 
2,901 (48.46%) 
1,437 (24.00%) 
1,219 (20.36%) 
430 (7.18%) 
2,827 (45.71%) 
1,523 (24.62%) 
1,393 (22.52%) 
442 (7.15%) 
2,645 (43.24%) 
1,446 (23.64%) 
1,547 (25.29%) 
479 (7.83%) 
a The variables with missing data were blood pressure, HDL level, LDL level, TG level, Smoking history, eGFR 
category, Body Mass Index ≥30kg/m2, Hemoglobin concentration, baseline CD4+ count and baseline viral load. 
Please see Appendix for details. 
Abbreviations used: SD, standard deviation; IQR, interquartile range; CHD, coronary heart disease; HDL high 
density lipoprotein; LDL, low density lipoprotein; HIV, Human Immunodeficiency Virus; RNA, Ribonucleic Acid; 
NRTI, Nucleoside Reverse Transcriptase Inhibitor, NNRTI, Non-nucleoside Reverse Transcriptase Inhibitor; PI, 
Protease Inhibitor.  
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3.2 RATES OF MI 
There were 766 cases of MI observed during the entire follow-up period, giving a rate of 18.49 
per 10,000 person years (95% CI: 16.95 to 20.17) among HIV-uninfected Veterans and 28.52 per 
10,000 person years (95% CI: 25.24 to 32.22) among HIV-infected Veterans. As shown in 
Tables 2 and 3, the rates of MI were consistently higher among HIV-infected Veterans, 
regardless of the CD8+ T-cell count stratification, compared to HIV-uninfected Veterans. The 
highest rate of MI was seen in the HIV-infected group within the CD8+ T-cell category ≥1066 
cells/mm3 with a rate of 32.20 per 10,000 person years (95% CI: 26.50 to 39.14), when 
participants were stratified based on only their HIV status and CD8+ T-cell count (Table 2). MI 
rates were also compared with all-cause mortality rates for each category (Tables 2 and 3).  
Table 2. MI Rates compared with Mortality Rates, by Baseline CD8+ T-cell Level 
(per 10,000 person years) 
No. of MI 
Events 
MI Rate a (95% CI) No. of Deaths Mortality Rate 
HIV-uninfected 508 18.49 (16.95 – 20.17) 4,674 18.63 (18.10 – 19.17) 
HIV-infected 
 CD8+ ≤ 666 cells/mm3 
 CD8+ 667 – 1065 cells/mm3 
 CD8+ ≥ 1066 cells/mm3 
 72 
 85 
101 
26.08 (20.70 – 32.86) 
26.98 (21.81 – 33.37) 
32.20 (26.50 – 39.14) 
1,449 
1,005 
1,045 
63.17 (60.00 – 66.51) 
38.54 (36.23 – 41.00) 
40.89 (38.49 – 43.45) 
a 1 missing record (0.0014% of the total) 
Abbreviations used: HIV, Human Immunodeficiency Virus; MI, Myocardial infarction 
When participants were stratified based on their HIV status and CD8+ T-cell count in the 
context of their baseline CD4+ T-cell count using clinical cut-points (Table 3, Figure 2), the rates 
of MI were again consistently higher among HIV-infected Veterans.  
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The highest MI rates were seen in the following instances: 
1)
within the highest tertile of CD8+ T cells (for the CD4+ T cells ≥ 500 cells/mm3 category) 
with MI rate of 28.68 per 10,000 person years (95% CI: 20.96 to 39.26). This tertile also had 
the highest mortality rate within this CD4+ T-cell category.
2)
within the highest tertile of CD8+ T cells (for the CD4+ T cells 200–499 cells/mm3 category) 
with MI rate of 37.38 per 10,000 person years (95% CI: 28.25 to 49.46). The mortality rate
Table 3. MI Rates compared with Mortality Rates by Baseline CD4+T-cell Clinical 
Cut-points and Baseline CD8+ T-cell Level (per 10,000 person years) 
No. of MI 
Events 
MI Rate a No. of 
Deaths 
Mortality Rate 
HIV-uninfected 508 18.49 (16.95 – 20.17) 4,674 18.63 (18.10 – 19.17) 
HIV-infected 
CD4+ ≥ 500 cells/mm3 
 CD8+ ≤ 666 cells/mm3 
 CD8+ 667 – 1065 cells/mm3 
 CD8+ ≥ 1066 cells/mm3 
 16 
 31 
39 
24.00 (14.70 – 39.18) 
26.68 (18.76 – 37.93) 
28.68 (20.96 – 39.26) 
 160 
 242 
 340 
28.08 (24.05 – 32.78) 
24.83 (21.89 – 28.17) 
30.66 (27.57 – 34.10) 
CD4+ 200-499 cells/mm3 
 CD8+ ≤ 666 cells/mm3 
 CD8+ 667 – 1065 cells/mm3 
 CD8+ ≥ 1066 cells/mm3 
 23 
 36 
49 
21.54 (14.32 – 32.42) 
26.08 (18.81 – 36.16) 
37.38 (28.25 – 49.46) 
 464 
 428 
 387 
43.88 (39.72 – 48.48) 
37.68 (34.27 – 41.42) 
43.52 (39.74 – 47.67) 
CD4+ < 200 cells/mm3 
 CD8+ ≤ 666 cells/mm3 
 CD8+ 667 – 1065 cells/mm3 
 CD8+ ≥ 1066 cells/mm3 
33 
18 
13 
32.16 (22.86 – 45.23) 
29.60 (18.65 – 46.97) 
27.89 (16.19 – 48.02) 
902 
335 
241 
107.13 (100.36 – 114.35) 
67.40 (60.56 – 75.02) 
63.32 (55.81 – 71.85) 
a 1 missing record (0.0014% of the total) 
Abbreviations used: HIV, Human Immunodeficiency Virus; MI, Myocardial infarction 
for this tertile was 0.36 per 10,000 person years below the highest mortality rate within this 
CD4+ T-cell category; and  
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3) within the lowest tertile of CD8+ T cells (for the CD4+ T cells < 200 cells/mm3 category),
with MI rate of 32.16 per 10,000 person years (95% CI: 22.86 – 45.23). The mortality rate
was highest in this tertile for this CD4+ T-cell category.
The MI rates among HIV-infected participants were observed to have overlapping 95% 
confidence intervals. All-cause mortality appeared to rise with decreasing CD4+ T-cell levels. 
Figure 2. Rates of MI and Rates of All-cause mortality by T-cell count 
3.3 ESTIMATES OF SURVIVAL FUNCTION 
Kaplan-Meier estimates of survival time to MI were graphed to show the survival distribution of 
the different CD8+ T-cell categories (see Appendix for Risk tables). When Veterans were 
stratified by HIV-CD8+ T-cell status alone (Figure 3), the estimated survival functions for the 
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lowest and highest CD8+ tertile (≤666 and >1065 cells/mm3 respectively) were seen to be very 
similar to each other. In contrast, the curve for the middle CD8+ tertile (666-1065 cells/mm3) was 
similar to the HIV-uninfected participants for the most part until after about four years of follow-
up time. Median survival time was not observed in any of the categories, indicating the rarity of 
MI events in this cohort. 
Figure 3. Graph of Kaplan-Meier survival estimates of MI development for different HIV/ 
CD8+ T-cell strata 
Abbreviations used: HIV- , HIV-uninfected; HIV+, HIV-infected. 
When Veterans were stratified by both CD8+ T-cell and CD4+ T-cell levels according to 
HIV status (Figure 4), the Kaplan-Meier curves were less distinct due to the number of groups. 
However, formal tests of the equality of survival functions revealed that the survival experiences 
of different CD8+ categories within each CD4+ T-cell level were not statistically different from 
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one another (see Appendix). One category among the HIV-infected Veterans seemingly had a 
‘better’ initial survival experience than the HIV-uninfected group (Figure 4). Subsequent 
investigation revealed this to be as a result of the relatively fewer number of participants in this 
category early in the follow-up period – hence fewer MI events were recorded during that period. 
Figure 4. Graph of Kaplan-Meier survival estimates of MI development for different HIV/ 
CD8+ T-cell strata by CD4+ T-cell level 
Abbreviations used: HIV- , HIV-uninfected; HIV+, HIV-infected. 
3.4 ESTIMATED MI RISK 
Proportional hazard models showed that MI risk was greatest among HIV-infected participants in 
the highest CD8+ T-cell tertile compared with HIV-uninfected participants (Table 4), following 
adjustment for all covariates (Hazard ratio, HR= 1.82, 95% CI: 1.46 to 2.28, P <0.001).  
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With additional stratification by CD4+ T-cell clinical cut-points (Table 4), MI risk was 
greatest among those within the highest CD8+ T-cell tertile who were also in the CD4+ T-cell 
category of either ≥500 cells/mm3 (adjusted HR = 1.69, 95% CI: 1.21 to 2.36, P = 0.002) or 200–
499 cells/mm3 (adjusted HR = 2.08, 95% CI: 1.53 to 2.82, P <0.001). Persons who were in the 
CD4+ T-cell category of <200 cells/mm3 were at greatest risk for MI if they were 
correspondingly within the lowest CD8+ T-cell tertile (adjusted HR = 1.82, 95% CI: 1.26 to 2.64, 
P = 0.001).  
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Table 4. Multivariable-adjusted Hazard Ratios (HR) for the association between CD8+ T-
cell levels and MI 
(continued) 
Covariates HR (95% CI)a P value HR (95% CI)b P value 
HIV status 
HIV-uninfected 1.00 (reference) 1.00 (reference) 
HIV infected by CD8+ count 
 CD8+ ≤ 666 cells/mm3 
 CD8+ 667 – 1065 cells/mm3 
 CD8+ ≥ 1066 cells/mm3 
1.45 (1.12 – 1.88) 
1.54 (1.21 – 1.96) 
 1.82 (1.46 – 2.28) 
 0.005 
 <0.001 
 <0.001 
…
…
…
…
…
…
HIV infected by CD4+ & CD8+ count 
CD4+ ≥ 500 cells/mm3 
 CD8+ ≤ 666 cells/mm3 
 CD8+ 667 – 1065 cells/mm3 
 CD8+ ≥ 1066 cells/mm3 
CD4+ 200-499 cells/mm3 
 CD8+ ≤ 666 cells/mm3 
 CD8+ 667 – 1065 cells/mm3 
 CD8+ ≥ 1066 cells/mm3 
CD4+ < 200 cells/mm3 
 CD8+ ≤ 666 cells/mm3 
 CD8+ 667 – 1065 cells/mm3 
 CD8+ ≥ 1066 cells/mm3
…
…
…
 
…
…
…
 
…
…
…
…
…
…
 
…
…
…
 
…
…
…
1.30 (0.76 – 2.20) 
1.51 (1.03 – 2.21) 
1.69 (1.21 – 2.36) 
1.22 (0.80 – 1.87) 
1.47 (1.03 – 2.09) 
2.08 (1.53 – 2.82) 
1.82 (1.26 – 2.64) 
1.80 (1.10 – 2.94) 
1.51 (0.85 – 2.67) 
0.339 
0.037 
0.002 
0.360 
0.034 
<0.001 
0.001 
0.019 
0.158 
Age (in 10-year increments) 1.80 (1.66 – 1.96) <0.001 1.81 (1.66 – 1.96) <0.001 
Female 0.34 (0.14 – 0.82) 0.017 0.34 (0.14 – 0.82) 0.017 
Race/ethnicity 
 African American 
 Hispanic  
 White 
 Other 
0.74 (0.63 – 0.87) 
1.07 (0.83 – 1.38) 
1.00 (reference) 
0.59 (0.39 – 0.88) 
<0.001 
0.602 
0.009 
0.74 (0.63 – 0.87) 
1.07 (0.83 – 1.38) 
1.00 (reference) 
0.59 (0.39 – 0.87) 
<0.001 
0.593 
0.009 
Traditional CHD risk factors 
Blood pressure (BP)  
 Non-hypertensive 
 Controlled-hypertensive 
 Uncontrolled-hypertensive 
1.00 (reference) 
1.36 (1.07 – 1.72) 
1.66 (1.42 – 1.95) 
0.013 
<0.001 
1.00 (reference) 
1.36 (1.07 – 1.72) 
1.67 (1.42 – 1.96) 
0.013 
<0.001 
Diabetes 1.74 (1.48 – 2.04) <0.001 1.74 (1.48 – 2.04) <0.001 
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Table 4. (continued) 
Covariates HR (95% CI)a P value HR (95% CI)b P value 
Lipid profile 
 Triglycerides ≥ 150 mg/dl  
 HDL cholesterol ≥ 60 mg/dl 
 HDL cholesterol 40 - 59 mg/dl 
 HDL cholesterol < 40 mg/dl    
 LDL cholesterol <100 mg/dl 
 LDL cholesterol 100-129 mg/dl 
 LDL cholesterol 130-159 mg/dl 
 LDL cholesterol ≥ 160 mg/dl   
1.17 (0.99 – 1.37) 
 1.00 (reference) 
1.02 (0.79 – 1.33) 
1.05 (0.81 – 1.36) 
 1.00 (reference) 
1.15 (0.95 – 1.38) 
1.54 (1.23 – 1.93) 
1.71 (1.33 – 2.21) 
0.058 
0.862 
0.724 
0.145 
<0.001 
<0.001 
1.17 (0.99 – 1.37) 
1.00 (reference) 
1.02 (0.79 – 1.33) 
1.04 (0.80 – 1.36) 
1.00 (reference) 
1.15 (0.96 – 1.38) 
1.55 (1.24 – 1.94) 
1.72 (1.34 – 2.22) 
0.059 
0.860 
0.743 
0.139 
<0.001 
<0.001 
Body Mass Index ≥ 30kg/m2 0.99 (0.83 – 1.17) 0.895 0.99 (0.84 – 1.17) 0.914 
Smoking history 
 Never 
 Past 
 Current 
 1.00 (reference) 
1.07 (0.82 – 1.40) 
1.73 (1.43 – 2.09) 
0.591 
<0.001 
1.00 (reference) 
1.08 (0.83 – 1.40) 
1.72 (1.42 – 2.09) 
0.575 
<0.001 
Other risk factors 
Hepatitis C virus infection 1.17 (0.98 – 1.40) 0.087 1.17 (0.98 – 1.40) 0.082 
Estimated Glomerular Filtration 
Rate (eGFR)  
 eGFR ≥ 60 ml/min/1.73m2
 eGFR  30 - 59 ml/min/1.73m2
 eGFR < 30 ml/min/1.73m2 
1.00 (reference) 
1.50 (1.16 – 1.95) 
3.23 (2.14 – 4.86) 
0.002 
<0.001 
1.00 (reference) 
1.50 (1.16 – 1.95) 
3.28 (2.17 – 4.95) 
0.003 
<0.001 
Use of Statins 0.85 (0.68 – 1.06) 0.147 0.85 (0.68 – 1.06) 0.149 
Hemoglobin (Hb) 
 Hb ≥ 14.0 mg/dl 
 Hb 12.0 – 13.9 mg/dl 
 Hb 10.0 – 11.9 mg/dl 
 Hb < 10.0 mg/dl 
1.00 (reference) 
1.23 (1.03 – 1.47) 
2.13 (1.61 – 2.81) 
2.13 (1.29 – 3.52) 
0.024 
<0.001 
0.003 
1.00 (reference) 
1.22 (1.02 – 1.47) 
2.09 (1.58 – 2.77) 
2.03 (1.22 – 3.38) 
0.028 
<0.001 
0.007 
History of Substance Use 
Cocaine abuse or dependence 1.01 (0.74 – 1.38) 0.969 1.00 (0.73 – 1.37) 0.984 
Alcohol  abuse or dependence  1.11 (0.87 – 1.41) 0.403 1.11 (0.87 – 1.41) 0.405 
a Model when CD8+ T-cell level was not stratified by CD4+ T-cell clinical cut-point 
b Model when CD8+ T-cell level was stratified by CD4+ T-cell clinical cut-point 
Abbreviations used: CHD, coronary heart disease; HDL high density lipoprotein; LDL, low density lipoprotein; 
HIV, Human Immunodeficiency Virus.  
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As the median age of members of the cohort was approximately 50 years (middle age) in 
all HIV-CD8+ T-cell categories, proportional hazard models restricted to those either above or 
below this age were analyzed (Table 5), to examine if there was an age effect affecting the 
previous results. A median of 50 years indicated that approximately half of the study participants 
fell either above or below this age. Effects of CD8+ T-cell counts lost statistical significance for 
most participant categories (likely due to reduced power). However, a consistent pattern of 
increasing MI risk with increasing CD8+ T-cell levels was observed across all CD4+ T-cell 
categories among those aged 50 years and above. The same pattern was seen in those below 50 
years with the exception of the CD4+ T-cell <200 cells/mm3 category. 
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Table 5. Multivariable-adjusted Hazard Ratios (HR) for the association between CD8+ T-
cell levels and MI for persons below or above middle age (50 years) 
(continued) 
Covariates HR (95% CI)a P value HR (95% CI)b P value 
HIV status 
HIV-uninfected 1.00 (reference) 1.00 (reference) 
HIV infected by CD4+ & CD8+ count 
CD4+ ≥ 500 cells/mm3 
 CD8+ ≤ 666 cells/mm3 
 CD8+ 667 – 1065 cells/mm3 
 CD8+ ≥ 1066 cells/mm3 
CD4+ 200-499 cells/mm3 
 CD8+ ≤ 666 cells/mm3 
 CD8+ 667 – 1065 cells/mm3 
 CD8+ ≥ 1066 cells/mm3 
CD4+ < 200 cells/mm3 
 CD8+ ≤ 666 cells/mm3 
 CD8+ 667 – 1065 cells/mm3 
 CD8+ ≥ 1066 cells/mm3 
0.87 (0.27 – 2.86) 
1.14 (0.56 – 2.34) 
1.52 (0.86 – 2.71) 
1.26 (0.58 – 2.72) 
1.29 (0.69 – 2.41) 
1.51 (0.82 – 2.75) 
1.93 (1.08 – 3.45) 
2.01 (0.96 – 4.18) 
0.64 (0.16 – 2.62) 
0.818 
0.718 
0.147 
0.554 
0.426 
0.183 
0.027 
0.062 
0.540 
1.55 (0.84 – 2.89) 
1.72 (1.09 – 2.71) 
1.77 (1.16 – 2.67) 
1.20 (0.71 – 2.04) 
1.57 (1.02 – 2.41) 
2.34 (1.63 – 3.34) 
1.63 (1.00 – 2.66) 
1.65 (0.85 – 3.19) 
 1.87 (1.00 – 3.52) 
0.163 
0.019 
0.007 
0.495 
0.041 
<0.001 
0.052 
0.136 
0.050 
Female 0.19 (0.05 – 0.79) 0.022 0.49 (0.16 – 1.53) 0.221 
Race/ethnicity 
 African American 
 Hispanic  
 White 
 Other 
0.75 (0.57 – 0.99) 
1.03 (0.66 – 1.63) 
1.00 (reference) 
0.39 (0.16 – 0.96) 
0.044 
0.887 
0.041 
0.71 (0.58 – 0.86) 
1.08 (0.80 – 1.47) 
1.00 (reference) 
0.67 (0.43 – 1.06) 
0.003 
0.605 
0.086 
Traditional CHD risk factors 
Blood pressure (BP)  
 Non-hypertensive 
 Controlled-hypertensive 
 Uncontrolled-hypertensive 
1.00 (reference) 
1.94 (1.24 – 3.03) 
1.81 (1.38 – 2.38) 
0.003 
<0.001 
1.00 (reference) 
1.40 (1.05 – 1.86) 
1.78 (1.46 – 2.17) 
0.020 
<0.001 
Diabetes 2.04 (1.53 – 2.72) <0.001 1.70 (1.40 – 2.06) <0.001 
Lipid profile 
 Triglycerides ≥ 150 mg/dl  
 HDL cholesterol ≥ 60 mg/dl 
 HDL cholesterol 40 - 59 mg/dl 
 HDL cholesterol < 40 mg/dl    
 LDL cholesterol <100 mg/dl 
 LDL cholesterol 100-129 mg/dl 
 LDL cholesterol 130-159 mg/dl 
 LDL cholesterol ≥ 160 mg/dl   
1.30 (0.96 – 1.75) 
1.00 (reference) 
0.86 (0.56 – 1.33) 
0.88 (0.55 – 1.41) 
1.00 (reference) 
1.35 (0.94 – 1.96) 
1.94 (1.37 – 2.75) 
2.11 (1.31 – 3.39) 
0.088 
0.499 
0.596 
0.105 
<0.001 
0.003 
1.04 (0.85 – 1.26) 
1.00 (reference) 
1.12 (0.76 – 1.66) 
1.13 (0.80 – 1.58) 
1.00 (reference) 
1.07 (0.85 – 1.35) 
1.35 (0.99 – 1.85) 
1.46 (1.06 – 2.01) 
0.718 
0.542 
0.486 
0.557 
0.060 
0.020 
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Table 5. (continued) 
Covariates HR (95% CI)a P value HR (95% CI)b P value 
Body Mass Index ≥ 30kg/m2 1.16 (0.87 – 1.54) 0.312 0.79 (0.64 – 0.98) 0.029 
Smoking history 
 Never 
 Past 
 Current 
1.00 (reference) 
2.12 (1.44 – 3.11) 
1.44 (0.84 – 2.46) 
<0.001 
0.187 
1.00 (reference) 
1.40 (1.12 – 1.74) 
1.04 (0.79 – 1.38) 
0.003 
0.774 
Other risk factors 
Hepatitis C virus infection 1.58 (1.19 – 2.11) 0.002 0.90 (0.72 – 1.13) 0.369 
Estimated Glomerular Filtration 
Rate (eGFR)  
 eGFR ≥ 60 ml/min/1.73m2
 eGFR  30 - 59 ml/min/1.73m2
 eGFR < 30 ml/min/1.73m2 
1.00 (reference) 
1.55 (0.87 – 2.77) 
0.78 (0.19 – 3.24) 
0.134 
0.730 
1.00 (reference) 
1.83 (1.38 – 2.43) 
4.20 (2.71 – 6.51) 
<0.001 
<0.001 
Use of Statins 0.76 (0.48 – 1.21) 0.246 0.90 (0.70 – 1.15) 0.400 
Hemoglobin (Hb) 
 Hb ≥ 14.0 mg/dl 
 Hb 12.0 – 13.9 mg/dl 
 Hb 10.0 – 11.9 mg/dl 
 Hb < 10.0 mg/dl 
1.00 (reference) 
1.24 (0.90 – 1.72) 
2.38 (1.42 – 4.02) 
2.36 (0.94 – 5.95) 
0.189 
0.001 
0.068 
1.00 (reference) 
1.32 (1.07 – 1.63) 
2.23 (1.61 – 3.10) 
2.17 (1.18 – 4.00) 
0.010 
<0.001 
0.012 
History of Substance Use 
Cocaine abuse or dependence 1.15 (0.73 – 1.81) 0.536 0.81 (0.52 – 1.28) 0.370 
Alcohol  abuse or dependence 1.00 (0.67 – 1.48) 0.995 1.07 (0.79 – 1.45) 0.674 
a Model restricted to persons below 50 years old 
b Model restricted to persons 50 years old and above 
Abbreviations used: CHD, coronary heart disease; HDL high density lipoprotein; LDL, low density lipoprotein; 
HIV, Human Immunodeficiency Virus.  
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Additionally, a proportional hazards model specific to HIV-infected Veterans (Table 6) 
revealed that MI risk was greatest among those within the highest and middle CD8+ T-cell 
tertiles compared to the lowest CD8+ T-cell tertile following adjustments for viral load and 
antiretroviral therapy, but this was not statistically significant (adjusted HR = 1.25 and 1.07 
respectively, P = 0.164 and 0.690 respectively, Table 6). A proportional hazards model with 
CD8+ T-cell count as a continuous variable, for HIV- infected Veterans only (Table 6), revealed 
that the MI risk increased by 0.03% for every additional cell/mm3 of CD8+ T-cell count 
(P=0.004). The exclusion of the baseline CD4+ T-cells variable from these two proportional 
hazard models just described did not reveal any marked changes in hazard ratios or standard 
errors (analyses not shown).  
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Table 6. Multivariable-adjusted Hazard Ratios (HR) for the association between CD8+ T-
cell levels and MI in HIV-Infected Veterans only 
(continued) 
Covariates HR (95% CI)a P value HR (95% CI)b P value 
HIV infected by CD8+ count strata 
 CD8+ ≤ 666 cells/mm3 
 CD8+ 667 – 1065 cells/mm3 
  CD8+ ≥ 1066 cells/mm3
 1.00 (reference) 
1.07 (0.77 – 1.47) 
1.25 (0.91 – 1.72) 
0.690 
0.164 
…
…
…
…
…
…
HIV infected with CD8+ count as 
continuous variable 
… … 1.0003 
(1.0001 – 1.0005) 
0.004 
Age (in 10-year increments) 1.74 (1.50 – 2.01) <0.001 1.74 (1.50 – 2.01) <0.001 
Female 0.41 (0.10 – 1.68) 0.217 0.42 (0.10 – 1.71) 0.224 
Race/ethnicity 
 African American 
 Hispanic  
 White 
 Other 
0.70 (0.52 – 0.93) 
0.92 (0.59 – 1.45) 
1.00 (reference) 
0.63 (0.32 –1.24) 
0.014 
0.727 
0.182 
0.69 (0.52 – 0.92) 
0.93 (0.59 – 1.47) 
1.00 (reference) 
0.63 (0.32 –1.24) 
0.013 
0.756 
0.181 
Traditional CHD risk factors 
Blood pressure (BP)  
 Non-hypertensive 
 Controlled-hypertensive 
 Uncontrolled-hypertensive 
1.00 (reference) 
1.72 (1.13 – 2.61) 
1.96 (1.49 – 2.58) 
0.011 
<0.001 
1.00 (reference) 
1.73 (1.13 – 2.63) 
1.96 (1.49 – 2.58) 
0.011 
<0.001 
Diabetes 1.54 (1.15 – 2.06) 0.004 1.53 (1.15 – 2.05) 0.004 
Lipid profile 
 Triglycerides ≥ 150 mg/dl  
 HDL cholesterol ≥ 60 mg/dl 
 HDL cholesterol 40 - 59 mg/dl 
 HDL cholesterol < 40 mg/dl    
 LDL cholesterol <100 mg/dl 
 LDL cholesterol 100-129 mg/dl 
 LDL cholesterol 130-159 mg/dl 
 LDL cholesterol ≥ 160 mg/dl   
1.36 (1.03 – 1.81) 
1.00 (reference) 
1.08 (0.64 – 1.83) 
1.04 (0.60 – 1.81) 
1.00 (reference) 
1.02 (0.73 – 1.44) 
1.69 (1.17 – 2.43) 
1.26 (0.74 – 2.15) 
0.030 
0.773 
0.889 
0.902 
0.005 
0.388 
1.36 (1.02 – 1.80) 
1.00 (reference) 
1.08 (0.63 – 1.82) 
1.02 (0.59 – 1.78) 
1.00 (reference) 
1.02 (0.72 – 1.44) 
1.68 (1.17 – 2.42) 
1.26 (0.74 – 2.14) 
0.034 
0.785 
0.931 
0.907 
0.005 
0.398 
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Table 6. (continued) 
Covariates HR (95% CI)a P value HR (95% CI)b P value 
Body Mass Index ≥ 30kg/m2 1.18 (0.84 – 1.66) 0.344 1.17 (0.83 – 1.64) 0.373 
Smoking history 
 Never 
 Past 
 Current 
1.00 (reference) 
1.12 (0.75 – 1.67) 
1.47 (1.07 – 2.04) 
0.580 
0.019 
1.00 (reference) 
1.13 (0.76 – 1.68) 
1.48 (1.07 – 2.04) 
0.557 
0.018 
Other risk factors 
Hepatitis C virus infection 1.29 (0.98 – 1.69) 0.065 1.30 (0.97 – 1.70) 0.062 
Estimated Glomerular Filtration 
Rate (eGFR)  
 eGFR ≥ 60 ml/min/1.73m2
 eGFR  30 - 59 ml/min/1.73m2
 eGFR < 30 ml/min/1.73m2 
1.00 (reference) 
1.44 (0.96 – 2.17) 
3.29 (1.25 – 4.57) 
0.081 
0.008 
1.00 (reference) 
1.43 (0.95 – 2.16) 
2.42 (1.27 – 4.62) 
0.086 
0.007 
Use of Statins 1.03 (0.69 – 1.54) 0.876 1.04 (0.70 – 1.55) 0.856 
Hemoglobin (Hb) 
 Hb ≥ 14.0 mg/dl 
 Hb 12.0 – 13.9 mg/dl 
 Hb 10.0 – 11.9 mg/dl 
 Hb < 10.0 mg/dl 
1.00 (reference) 
1.29 (0.95 – 1.75) 
2.06 (1.35 – 3.16) 
1.57 (0.71 – 3.49) 
0.107 
0.001 
0.264 
1.00 (reference) 
1.29 (0.95 – 1.76) 
2.09 (1.36 – 3.20) 
1.62 (0.73 – 3.59) 
0.103 
0.001 
0.236 
Hx of Substance Use 
Cocaine abuse or dependence 0.97 (0.59 – 1.59) 0.900 0.98 (0.60 – 1.60) 0.938 
Alcohol  abuse or dependence  1.15 (0.76 – 1.76) 0.504 1.15 (0.75 – 1.75) 0.526 
Baseline Laboratory Analysis 
CD4+ T-cell level 
≥500 cells/ mm3 
200 – 499 cells/ mm3 
<200 cells/ mm3 
1.00 (reference) 
1.06 (0.78 – 1.44) 
1.22 (0.84 – 1.77) 
0.706 
0.302 
1.00 (reference) 
1.08 (0.80 – 1.46) 
1.27 (0.88 – 1.85) 
0.621 
0.200 
HIV-1 RNA copies/ mL 
<500 copies/ mL 
≥500 copies/ mL 
1.00 (reference) 
1.10 (0.82 – 1.48) 0.539 
1.00 (reference) 
1.08 (0.80 – 1.45) 0.620 
Antiretroviral therapy use 
 None 
 NRTI + NNRTI 
 NRTI + PI 
 Other combination 
1.00 (reference) 
0.87 (0.62 – 1.22) 
1.01 (0.63 – 1.62) 
0.99 (0.71 – 1.39) 
0.428 
0.962 
0.974 
1.00 (reference) 
0.88 (0.63 – 1.24) 
1.02 (0.63 – 1.63) 
1.00 (0.72 – 1.40) 
0.465 
0.942 
0.989 
a Model when CD8+ T-cell level is treated as a categorical variable 
b Model when CD8+ T-cell level is treated as a continuous variable 
Abbreviations used: CHD, coronary heart disease; HDL high density lipoprotein; LDL, low density lipoprotein; 
HIV, Human Immunodeficiency Virus; RNA, Ribonucleic Acid; NRTI, Nucleoside Reverse Transcriptase Inhibitor, 
NNRTI, Non-nucleoside Reverse Transcriptase Inhibitor; PI, Protease Inhibitor.  
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The assumption of proportional hazards was not violated when participants were 
stratified by HIV status and CD8+ T-cell level only (see Appendix). However when the HIV-
infected participants were further stratified by CD4+ T-cell level, the proportional hazards 
assumption was not met for the middle and low CD8+ T-cell tertiles within the CD4+ ≥500 
cells/mm3 category (i.e. 667-1065 and ≤666 cells/mm3 groups). 
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4.0  DISCUSSION 
This study examined whether an association exists between baseline total CD8+ T-cell count and 
the risk of MI, in the setting of HIV, in a large, representative cohort. It is of Public Health 
importance in that the study findings may help improve the current management of HIV-infected 
persons, especially with regards to their MI risk. 
In the sample of VACS-VC participants assessed, high CD8+ T-cell counts (≥1066 
cells/mm3) were associated with the greatest risk of MI. This was demonstrated in regression 
models that considered both HIV-infected and HIV-uninfected participants and in secondary 
analysis restricted to HIV-infected participants. These results are in agreement with an earlier 
study by Lang et al which showed that, as an independent predictor, high CD8+ T-cell counts are 
associated with an increased risk for MI [2]. They also agree with studies that looked at 
surrogates for MI (subclinical carotid artery disease), which showed that the risk was increased 
in the presence of markers for immune activation, including a low CD4+/CD8+ T-cell ratio [16, 
17]. However, CD4+/CD8+ ratios may be very similar despite the individual being at different 
spectrums of HIV disease progression and thus, perhaps, at a different risk for MI (Figure 1). 
The approach used in this current study attempts to overcome this obstacle by making use of the 
actual T-cell counts. And it goes a step further by taking into account risk stratification for CD8+ 
T cells based on clinically-relevant CD4+ T-cell cut-points. 
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CD4+ T-cell counts have long been established into clinically relevant cut-points [33]. 
HIV-infected persons with values ≥500 cells/mm3 are considered closer to a “normal” immune 
status and experience fewer co-morbid conditions while those with values <200 cells/mm3 are 
generally at a higher risk of co-morbid disease and have a severely compromised immune status. 
CD4+ T-cell counts have thus been used as a proxy for the status of the immune system [33]. 
Harnessing these facts, an association of CD8+ T-cell counts with MI risk is probably best 
viewed in the context of the person’s immune status. Indeed, these T-cell populations exhibit a 
dynamism that should be accounted for within the limits of clinical relevance and resources 
available to research. 
When viewed in the context of baseline CD4+ T-cell clinical cut-points, the MI risk 
associated with the CD8+ T-cell count varied. Persons with a high CD8+ T-cell count may be at 
most risk for MI events if with a CD4+ T-cell count ≥500 cells/mm3 or 200–499 cells/mm3. In 
contrast, when the CD4+ T-cell count was low (<200 cells/mm3), the risk of MI appeared to be 
greatest among those persons with an equally low CD8+ count (≤666 cells/mm3).   
The results from this present study do not disagree with the usefulness of CD4+ T cells in 
determining the risk of comorbid disease in HIV. Rather they optimize its value in specifically 
determining the risk of MI in the setting of HIV. These findings were also consistent with the 
rates of MI observed in this cohort.   
The reasons why MI risk associated with CD8+ T-cell count differs depending on the 
status of the immune system are unclear at present, yet a potential explanation is presented here: 
HIV-infected individuals who do not have a low immune status (i.e. CD4+ T cell counts ≥500 
cells/mm3 or 200–499 cells/mm3) appeared to be at greatest risk for MI if their baseline CD8+ T-
cell count was also high (≥1066 cells/mm3). This may be a reflection of the damage to 
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endothelial cells and arterial walls due to increased amounts of pro-inflammatory cytokines and 
oxidative stress brought about by such high numbers of this cell type. The immune mechanisms 
behind the pathogenesis of atherosclerosis (a common precedent for MI) have been well-
described in the literature [49].  
That HIV-infected Veterans with a low immune status (CD4+ T-cell counts <200 
cells/mm3) appeared to be at greatest MI risk when their CD8+ T-cell count was also low (≤666 
cells/mm3) may not be entirely true. Proportional hazard models restricted to persons above and 
below the median age of approximately 50 years showed the pattern of CD8+ T-cell effect 
persisted in the older age group across all CD4+ T-cell strata; i.e. those ≥50 years of age had an 
increasing MI risk with increasing levels of CD8+ T cells. Some categories lacked statistical 
significance and this may be due to a reduction in statistical power from the stratification. 
Veterans below 50 years of age had a different CD8+ T-cell effect in the CD4+ T-cell <200 
cells/mm3 stratum, which did not appear to follow a distinct pattern. This may be due to a 
relatively lower sample size in these CD8+ T-cell categories for persons in that CD4+ T-cell 
stratum, leading to a reduction in statistical power. In addition, this CD4+ T-cell stratum is 
associated with a severely compromised immune status: the competing risks of mortality from 
other comorbid conditions may have precluded the observance of MI events. 
It should be noted that the effects of CD8+ T-cell levels appeared to have a larger effect 
size for the older age group in all CD4+ T-cell strata: With the exception of the CD4+ T-cell 200-
499, CD8+ T-cell ≤666 cells/mm3 group, more than 50% in each of the CD8+ T-cell categories 
were at greater MI risk than HIV-uninfected participants across all CD4+ T-cell strata compared 
to the younger age group. Whether a biological reason might be responsible for this is unclear at 
present.  
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In the regression model restricted to HIV-infected participants the trend of increasing MI 
risk with increasing CD8+ T-cell level compared to the lowest CD8+ tertile may have lacked 
statistical significance because of the reduced sample size (18,289) which potentially reduced 
statistical power. Less than half (258) of the 766 MI events observed were among HIV-infected 
Veterans. However, when CD8+ T-cell count was treated as a continuous variable in the HIV-
restricted model, it was observed that the risk of MI increased for every unit increase in CD8+ T-
cell count. This supports the findings from the previous results that MI risk does indeed appear to 
be greater with an increasing CD8+ T-cell level. A linear relationship between CD8+ T-cell 
counts and MI risk should not be necessarily assumed in this cohort however, as there was a 
wide range in the observed CD8+ T-cell counts. 
It should also be noted that the differences in the effect of CD8+ T-cell counts appeared to 
be most marked in the group with CD4+ T-cell levels of 200-499 cells/mm3. This effect was 
observed in all the regression models and reflected in the observed MI rates as well. This may 
indicate that that even though a high CD8+ level is associated with an increased MI risk 
compared to uninfected persons, this relationship may be most useful in persons within this 
particular CD4+ T-cell level. The violation of proportional hazards for the middle and low CD8+ 
T-cell tertiles within the CD4+ ≥500 cells/mm3 category does not signify that the hazard ratios 
for these groups are non-informative. The ratios reveal the average effect for these groups, with 
the caveat that these ratios do not change proportionally with time. Moreover, proportional 
hazards regression models are often robust to slight changes in proportionality: it was observed 
that the non-proportionality appeared in the latter stages of the follow-up period (see log-log plot 
in Appendix).   
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This study confirmed that HIV-uninfected Veterans are at the least risk for MI as 
suggested by recent research [1]. It also showed that the risk of MI posed by traditional risk 
factors, demographic variables and other risk factors such as substance abuse, statin use and 
Hepatitis C virus infection virtually remained unchanged irrespective of whether the CD8+ T-cell 
count was stratified by CD4+ T-cell clinical cut-points or not. These factors should therefore be 
considered whenever assessing patients for MI risk.  
In addition, this study compared rates of MI with HIV-uninfected persons as part of the 
study sample, utilized a large cohort and had clinically adjudicated MI outcomes. By making use 
of baseline CD4+ and CD8+ T-cell counts to determine MI risk, it also closely reproduced the 
setting in a physician clinic whereby reliable risk stratification for MI (or another comorbid 
disease) is often based on laboratory values obtained from that clinic visit.  
The study had some limitations. It did not explore whether the changes in total CD8+ T-
cell counts were due to changes in HIV-specific CD8+ T cells nor did it examine markers for 
CD8+ T-cell immune activation, such as CD38+. However, it should be noted that these measures 
are often not available for routine clinic visits and are expensive.  
Also, the stratification of the CD8+ T-cell count into tertiles was arbitrary, being based on 
the cohort and not on pre-existing clinical cut-points. Interestingly, these tertile levels are very 
similar to those reported in other studies [2, 50]. Stratification of the CD8+ T-cell count into 
tertiles enabled inclusion of HIV-uninfected Veterans into most of the analyses, through the 
creation of a “HIV-negative, no CD8+ count” variable. But, because these uninfected persons did 
not have CD8+ T-cell count measurements, the effects of CD8+ T cells as a continuous variable 
could not be explored for them. The drawbacks of categorizing data include reduced statistical 
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power, reduced information, concealed non-linearity relationships and possibly even an increase 
in Type I error rates.   
Another limitation was that time-updated covariates for CD8+ (and CD4+ T cells) were 
not used to determine MI risk. A time-updated model may have reflected the longitudinal 
changes in these two cell types and may have shown their relation with MI risk more clearly. 
Again, it should be stressed that this study was designed to simply determine associations 
between CD8+ T-cell counts and MI risk, especially associations that would be of immediate 
relevance when making a clinical decision. Hence, while more accurate prediction of MI risk 
might have been achievable with a time-updated model or by taking into account measures of 
CD8+ or CD4+ T-cell nadirs, or recent CD8+ or CD4+ T-cell counts shortly before an MI event, 
in most clinic situations these parameters are not foreseeable when deciding patient care.  
Yet another limitation was the demographic-makeup of the cohort: over 90% of the 
participants were male, so the study results may not be generalizable to females. Age-related 
factors may have also confounded the results. The proportional hazard model restricted to 
persons below the age of 50 years did not show a particular pattern of CD8+ T-cell effect in the 
CD4+ <200 cells/mm3 group (as discussed earlier). Future studies could address these problems. 
Additionally, while attempts were made to adjust for several known risk factors for MI, 
some confounding might still persist, especially with an ever-rapidly increasing number of non-
traditional risk factors being discovered. However, traditional risk factors for MI still play a 
major role in its determination [34] and it is believed that adjusting for them, as in this study, will 
have done much to offset the effects of any residual confounding.  
The all-cause mortality rates in the cohort showed that mortality increased with declining 
immune status and this may have posed some measure of competing-risk for the occurrence of 
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MI events. Mortality rates were most marked in the CD4+ T-cell <200 cells/mm3 category which 
may have affected the study findings in this category. Further research could resolve this issue. 
Being a large study cohort, there may also be a limitation due to the presence of missing 
data. However, the multiple imputation techniques instituted appear to have handled this 
appropriately, for the observed MI rates were very similar to the estimated hazard ratios for 
CD8+ T-cell count with and without stratification by CD4+ T-cell count. Although the descriptive 
rates and also estimated risks of MI were found to have overlapping 95% confidence intervals, 
this does not necessarily make them equivalent to each other. Indeed, overlapping confidence 
intervals do not indicate that two or more rates (or risks) are not significantly different [51, 52]. 
Prior work on the association between CD8+ T-cell subsets and AIDS progression has also 
revealed some overlap in the confidence intervals of the estimated hazard ratios [15]. Thus a 
reliance on P values for statistical significance alongside formal tests to differentiate between the 
various hazard-ratios may serve as a useful guide. Such interpretations should also take the 
sample size and statistical power into account. Tests of equality of the survivor function using 
Kaplan-Meier estimates showed that there was no statistically significant difference in survival 
experience between CD8+ T-cell categories among HIV-infected persons, for each level of CD4+ 
T-cells (see Appendix). Similarly, comparisons of hazard ratios within each CD4+ T-cell level 
revealed that there was no statistically significant difference in MI risk between the CD8+ 
categories (analyses not shown). More definitive studies may explain the reasons for this. 
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5.0  CONCLUSION 
In conclusion, data from this longitudinal cohort study of Veterans confirm that MI risk is greater 
among HIV-infected compared to HIV-uninfected individuals. The results suggest that the CD8+ 
T-cell count may be associated with an increased risk of MI, but the data are unclear. More 
specifically, the data would suggest that the CD8+ T-cell count may need to be interpreted in the 
context of the CD4+ T-cell count or overall immune status. They appear to be most informative 
when the individual has an immune status that is “near normal” (i.e. CD4+ T-cell count 200-499 
cells/mm3), with a high CD8+ T-cell count being associated with greater MI risk. CD8+ T-cell 
counts may help optimize CD4+ T-cell clinical cut-points and may offer useful risk stratification 
for MI. They offer a potential means for improving HIV-patient care using resources already 
available in most clinic settings. As results from this study are not definitive, more research into 
the relationship between CD8+ T-cell counts and MI is advised.   
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APPENDIX: SUPPLEMENTAL TABLES AND FIGURES 
Table A.1. Missing Data for Baseline Variables of HIV-uninfected and HIV-infected 
Veterans 
Covariate Total (n, %) HIV-uninfected (n, %) HIV-infected (n, %) 
Gender 0 0 0 
Race 0 0 0 
Diabetes 0 0 0 
Blood pressure 1,298 (1.77%) 1,141 (2.07%) 157 (0.86%) 
HDL level 18,924 (25.78%) 14,856 (26.96%) 4,338 (23.72%) 
LDL level 21,427 (29.19%) 16,546 (30.02%) 4,881 (26.69%) 
TG level 15,115 (20.59%) 12,621 (22.90%) 2,494 (13.64%) 
Statins use 0 0 0 
Smoking history 5,223 (7.12%) 4,233 (7.68%) 990 (5.41%) 
Hepatitis C status 0 0 0 
eGFR category 7,714 (10.51%) 6,954 (12.62%) 7,714 (4.16%) 
BMI ≥ 30 kg/ m2 1,733 (2.36%) 1,570 (2.85%) 163 (0.89%) 
Cocaine abuse 0 0 0 
Alcohol abuse 0 0 0 
Hemoglobin 9,911 (13.50%) 8,478 (15.38%) 1,433 (7.84%) 
Baseline CD4+ TCL 1,690 (9.24%) … 1,690 (9.24%) 
Baseline VL 1,448 (7.92%) … 1,448 (7.92%) 
ART Regimen 0 … 0 
Abbreviations: HDL, high density lipoprotein; LDL, low density lipoprotein; TG, Triglyceride; eGFR, estimated 
glomerular filtration rate; BMI, body mass index; TCL, T-cell level; VL, Viral load; ART, antiretroviral therapy. 
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Table A.2. Number of Persons at Risk at Specific Time Points during the Follow-up Period 
(Risk Tables) 
*All T-cell counts in cells/ mm3
Abbreviations used: HIV- , Human Immunodeficiency Virus uninfected; HIV+, Human Immunodeficiency Virus 
infected. 
UNSTRATIFIED BY CD4+ T-CELL LEVEL 
Risk category Time = 0 year Time = 2 years Time = 4 years Time = 6 years Time = 8 years 
HIV – 55,124 48,988 40,005 26,613 0 
HIV+, CD8+ ≤666 5,988 4,965 3,797 2,564 0 
HIV+, CD8+ 667-
1065 6,191 5,516 4,516 3,242 0 
HIV+, CD8+ ≥1066 6,121 5,498 4,486 3,264 0 
STRATIFIED BY CD4+ T-CELL LEVEL 
Risk category Time = 0 year Time = 2 years Time = 4 years Time = 6 years Time = 8 years 
HIV – 55,124 48,988 40,005 26,613 0 
CD4+ ≥500 
HIV+, CD8+ ≤666 1,297 1,152 954 707 0 
HIV+, CD8+ 667-
1065 2,186 2,006 1,689 1,270 0 
HIV+, CD8+  ≥1066 2,548 2,330 1,979 1,492 0 
CD4+ 200-499 
HIV+, CD8+ ≤666 2,137 1,883 1,523 1,081 0 
HIV+, CD8+ 667-
1065 2,686 2,410 1,981 1,425 0 
HIV+, CD8+ ≥1066 2,580 2,313 1,856 1,366 0 
CD4+ <200 
HIV+, CD8+ ≤666 2,554 1,930 1,320 776 0 
HIV+, CD8+ 667-
1065 1,319 1,100 846 547 0 
HIV+, CD8+ ≥1066 993 855 651 406 0 
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Table A.3. Test statistics, Degrees of Freedom and P values for the Equality of the Survival 
Functions for various participant groups 
Comparison Groups Statistica Value df P value 
All 4 groups stratified by HIV status 
and CD8+ tertile 
Tarone-Ware 35.05 3 <0.001 
Peto-Peto-Prentice 35.27 3 <0.001 
For HIV+, CD8+ ≤666 cells/mm3 
compared with CD8+ 667-1065 
cells/mm3 
Tarone-Ware 0.00 1 0.9736 b 
Peto-Peto-Prentice 0.02 1 0.8793 b 
For HIV+, CD8+ ≤666 cells/mm3 
compared with CD8+ ≥1065 
cells/mm3 
Tarone-Ware 1.13 1 0.2874 b 
Peto-Peto-Prentice 1.66 1 0.1971 b 
For HIV+, CD8+ 667-1065 cells/mm3 
compared with CD8+ ≥1065 
cells/mm3 
Tarone-Ware 1.30 1 0.2549 b 
Peto-Peto-Prentice 1.42 1 0.2332 b 
All 10 groups  when participants 
were stratified by HIV status and 
CD8+ tertile for each CD4+ T-cell 
level 
Tarone-Ware 42.22 9 <0.001 
Peto-Peto-Prentice 42.09 9 <0.001 
All CD8+ tertiles, for HIV+ with 
CD4+ ≥ 500 cells/ mm3 
Tarone-Ware 0.15 2 0.9281 b 
Peto-Peto-Prentice 0.31 2 0.8565 b 
All CD8+ tertiles, for HIV+ with 
CD4+ 200-499 cells/ mm3 
Tarone-Ware 5.04 2 0.0803 b 
Peto-Peto-Prentice 5.60 2 0.0609 b 
All CD8+ tertiles, for HIV+ with 
CD4+ <200 cells/ mm3 
Tarone-Ware 0.10 2 0.9497 b 
Peto-Peto-Prentice 0.20 2 0.9056 b 
a The Tarone-Ware and Peto-Peto-Prentice tests were chosen because the Kaplan Meier curves of estimated survival 
function (Figures 3 and 4) showed late differences in survival experience.  
b Bonferroni correction for alpha level of 0.0167 (i.e. 0.05/ 3) was used for these post-hoc comparisons. 
Abbreviations used: HIV- , Human Immunodeficiency Virus uninfected; HIV+, Human Immunodeficiency Virus 
infected. 
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Table A.4. Test statistics of Scaled Schoenfeld Residuals, Degrees of Freedom and P values 
for the tests of Proportional-Hazards assumptions for various proportional-hazards models 
using different functions of time 
UNSTRATIFIED BY CD4+ T-CELL LEVEL 
g(t) = t g(t) = In (t) g(t) = ŜKM (t) g(t) = rank (t) 
CD8+ 
category 
df chi2 
value 
P value chi2 
value 
P value chi2 
value 
P value chi2 
value 
P value 
HIV – 1  …  …  …  …  …  …  …  … 
HIV+, CD8+ 
≤666 
1 1.86 0.1731 2.54 0.1111 1.54 0.2140 2.15 0.1428 
HIV+, CD8+ 
667-1065 
1 0.37 0.5455 1.11 0.2923 0.23 0.6341 0.41 0.5196 
HIV+, CD8+ 
≥1066 
1 0.38 0.5391 0.75 0.3850 0.46 0.4970 0.36 0.5513 
STRATIFIED BY CD4+ T-CELL LEVEL 
g(t) = t g(t) = In (t) g(t) = ŜKM (t) g(t) = rank (t) 
Category df chi2 
value 
P value chi2 
value 
P value chi2 
value 
P value chi2 
value 
P value 
CD4+ ≥500 
HIV+, CD8+ 
≤666 
1 5.75 0.0165 5.72 0.0168 5.52 0.0188 6.28 0.0122 
HIV+, CD8+ 
667-1065 
1 6.46 0.0110 5.99 0.0144 5.90 0.0151 6.66 0.0098 
HIV+, CD8+ 
≥1066 
1 1.89 0.1696 1.00 0.3177 2.15 0.1422 1.80 0.1800 
CD4+ 200-499 
HIV+, CD8+ 
≤666 
1 0.00 0.9773 0.19 0.6607 0.01 0.9285 0.01 0.6523 
HIV+, CD8+ 
667-1065 
1 1.10 0.2947 0.18 0.6722 1.34 0.2465 1.04 0.3081 
HIV+, CD8+ 
≥1066 
1 0.21 0.6463 0.60 0.4382 0.25 0.6168 0.20 0.6523 
CD4+ <200 
HIV+, CD8+ 
≤666 
1 0.13 0.7157 0.13 0.7168 0.10 0.7567 0.15 0.6998 
HIV+, CD8+ 
667-1065 
1 0.24 0.6273 0.03 0.8674 0.23 0.6304 0.23 0.6287 
HIV+, CD8+ 
≥1066 
1 2.70 0.1006 0.61 0.4363 2.86 0.0909 2.62 0.1053 
*All T-cell counts in cells/mm3 
Abbreviations used: t , time; In (t) , natural logarithmic transformation of time; ŜKM (t) , Kaplan-Meier 
transformation of time; rank (t) , rank transformation of time; HIV- , Human Immunodeficiency Virus uninfected; 
HIV+, Human Immunodeficiency Virus infected. 
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Figure A.1. Log-log plot testing Proportional Hazards Assumptions for three HIV+, CD8+ 
T-cell categories compared to the HIV-uninfected group. 
Abbreviations used: HIV- , HIV-uninfected; HIV+ , HIV-infected. 
 
 
 
 
 
 
All T-cell counts in cells/mm
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